US commercial bank deposits fell $42 billion to $19.296 trillion, continuing a post-pandemic normalization trend with ...

Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria - ...

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial ...

Normalized earnings remove one-time events and seasonal shifts, offering a clear view of a company's genuine financial status ...

Newly released data reflects a normalization in consumer sentiment after heightened demand earlier in the year driven by the ...

Experian benefits from deeply embedded global banking partnerships and massive cloud-migrated datasets. Learn why EXPGY stock ...

Scouring through corporate communications and broker research isn’t enough Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The ...

Watchmaker Genomics, a leader in high-performance NGS workflow solutions, today announced it will unveil two new technologies ...

Across 76 weeks in obesity/overweight without type 2 diabetes, survodutide achieved up to 16.6% mean weight loss versus 3.2% ...

ODDITY Tech Ltd. (NASDAQ: ODD) today announced its financial results for the first quarter ended March 31, 2026. “We continue to implement our recovery plan to address the account dislocation with our ...

More often than not, pulling data from the internet can be a major pain in the behind. It lulls you into a false sense of accomplishment, since downloading a web page is the easy part. But when you ...

Combination tobevibart 300 mg + elebsiran 200 mg q4w achieved HDV RNA TND in 77% at week 72 and 88% at week 96, outperforming tobevibart monotherapy. Profound HBsAg lowering occurred with dual therapy ...